Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136,797 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The degree of intratumor mutational heterogeneity varies by primary tumor sub-site.
Ledgerwood LG, Kumar D, Eterovic AK, Wick J, Chen K, Zhao H, Tazi L, Manna P, Kerley S, Joshi R, Wang L, Chiosea SI, Garnett JD, Tsue TT, Chien J, Mills GB, Grandis JR, Thomas SM. Ledgerwood LG, et al. Among authors: wang l. Oncotarget. 2016 May 10;7(19):27185-98. doi: 10.18632/oncotarget.8448. Oncotarget. 2016. PMID: 27034009 Free PMC article.
Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer.
Bauman JE, Duvvuri U, Gooding WE, Rath TJ, Gross ND, Song J, Jimeno A, Yarbrough WG, Johnson FM, Wang L, Chiosea S, Sen M, Kass J, Johnson JT, Ferris RL, Kim S, Hirsch FR, Ellison K, Flaherty JT, Mills GB, Grandis JR. Bauman JE, et al. Among authors: wang l. JCI Insight. 2017 Mar 23;2(6):e90449. doi: 10.1172/jci.insight.90449. JCI Insight. 2017. PMID: 28352657 Free PMC article. Clinical Trial.
Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer.
Hedberg ML, Peyser ND, Bauman JE, Gooding WE, Li H, Bhola NE, Zhu TR, Zeng Y, Brand TM, Kim MO, Jordan RCK, VandenBerg S, Olivas V, Bivona TG, Chiosea SI, Wang L, Mills GB, Johnson JT, Duvvuri U, Ferris RL, Ha P, Johnson DE, Grandis JR. Hedberg ML, et al. Among authors: wang l. J Exp Med. 2019 Feb 4;216(2):419-427. doi: 10.1084/jem.20181936. Epub 2019 Jan 25. J Exp Med. 2019. PMID: 30683736 Free PMC article. Clinical Trial.
Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma.
Wheeler S, Siwak DR, Chai R, LaValle C, Seethala RR, Wang L, Cieply K, Sherer C, Joy C, Mills GB, Argiris A, Siegfried JM, Grandis JR, Egloff AM. Wheeler S, et al. Among authors: wang l. Clin Cancer Res. 2012 Apr 15;18(8):2278-89. doi: 10.1158/1078-0432.CCR-11-1593. Epub 2012 Feb 20. Clin Cancer Res. 2012. PMID: 22351687 Free PMC article.
Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.
Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, Maxwell J, Wang L, Gooding WE, Johnson DE, Grandis JR. Sen M, et al. Among authors: wang l. Clin Cancer Res. 2012 Sep 15;18(18):4986-96. doi: 10.1158/1078-0432.CCR-12-0792. Epub 2012 Jul 23. Clin Cancer Res. 2012. PMID: 22825581 Free PMC article.
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.
Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert BR, Freilino M, Sauerwein S, Peyser ND, Xiao D, Diergaarde B, Wang L, Chiosea S, Seethala R, Johnson JT, Kim S, Duvvuri U, Ferris RL, Romkes M, Nukui T, Kwok-Shing Ng P, Garraway LA, Hammerman PS, Mills GB, Grandis JR. Lui VW, et al. Among authors: wang l. Cancer Discov. 2013 Jul;3(7):761-9. doi: 10.1158/2159-8290.CD-13-0103. Epub 2013 Apr 25. Cancer Discov. 2013. PMID: 23619167 Free PMC article.
Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.
Gross ND, Bauman JE, Gooding WE, Denq W, Thomas SM, Wang L, Chiosea S, Hood BL, Flint MS, Sun M, Conrads TP, Ferris RL, Johnson JT, Kim S, Argiris A, Wirth L, Nikiforova MN, Siegfried JM, Grandis JR. Gross ND, et al. Among authors: wang l. Clin Cancer Res. 2014 Jun 15;20(12):3289-98. doi: 10.1158/1078-0432.CCR-13-3360. Epub 2014 Apr 11. Clin Cancer Res. 2014. PMID: 24727329 Free PMC article. Clinical Trial.
Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
Van Allen EM, Lui VW, Egloff AM, Goetz EM, Li H, Johnson JT, Duvvuri U, Bauman JE, Stransky N, Zeng Y, Gilbert BR, Pendleton KP, Wang L, Chiosea S, Sougnez C, Wagle N, Zhang F, Du Y, Close D, Johnston PA, McKenna A, Carter SL, Golub TR, Getz G, Mills GB, Garraway LA, Grandis JR. Van Allen EM, et al. Among authors: wang l. JAMA Oncol. 2015 May;1(2):238-44. doi: 10.1001/jamaoncol.2015.34. JAMA Oncol. 2015. PMID: 26181029 Free PMC article.
Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer.
Lui VW, Peyser ND, Ng PK, Hritz J, Zeng Y, Lu Y, Li H, Wang L, Gilbert BR, General IJ, Bahar I, Ju Z, Wang Z, Pendleton KP, Xiao X, Du Y, Vries JK, Hammerman PS, Garraway LA, Mills GB, Johnson DE, Grandis JR. Lui VW, et al. Among authors: wang l, wang z. Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1114-9. doi: 10.1073/pnas.1319551111. Epub 2014 Jan 6. Proc Natl Acad Sci U S A. 2014. PMID: 24395800 Free PMC article.
136,797 results
You have reached the last available page of results. Please see the User Guide for more information.